Buy Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients with:

  • CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
    Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).
  • Posology & Administration: The recommended dosage of Blincyto (blinatumomab injection) is administered as a continuous IV infusion for 28 consecutive days per cycle involving a 24/7 infusion followed by 14 days off from infusion. The dose mainly depends on a patient’s actual body weight. Patients weighing over 45 kg should receive fixed doses while patients weighing less than 45 kg should receive doses depending on their estimated body surface area.